Company Overview and News
New Delhi: The Delhi high court on Thursday directed Fortis Healthcare Ltd to file its reply and affidavit in an application moved by Japanese drugmaker Daiichi Sankyo seeking to prevent the sale of Fortis Healthcare to Manipal Health Enterprises.
Fortis Healthcare share price gained more than 5 percent intraday Friday after the Delhi Court asked company to respond on Daiichi's plea to stall restructuring process.
New Delhi: The Delhi high court on Friday ordered the attachment of all moveable property disclosed in an affidavit by former Ranbaxy Laboratories promoters, brothers Malvinder Singh and Shivinder Singh, and others in relation to a Rs3,500 crore arbitration case with Japanese drug maker Daiichi Sankyo Co. Ltd.
The Delhi High Court on Friday ordered attachment of all declared assets of Singh brothers in a case related to the enforcement of a foreign arbitration award of Rs 3,500 crore by Japanese drug maker Daiichi Sankyo, according to a CNBC-TV18 report.
The court restrained RHC Holdings from operating its bank accounts except for payment of salaries and statutory dues till March 23, the next date of hearing.
Delhi High Court has attached all assets of RHC Holdings and Oscar Investments. The court has restrained RHC Holdings and Oscar Investments from working bank accounts. They can operate bank accounts for salary and statutory dues.
New Delhi: The Delhi high court on Monday issued a warrant of attachment against all the assets disclosed by Oscar Investments Ltd and RHC Holding Pvt. Ltd, owned by Ranbaxy promoters Malvinder and Shivinder Singh, in their 2 December 2016 and 14 March 2017 affidavits submitted to the court.
In a major blow to Singh brothers – the promoters of Fortis Healthcare and Religare Enterprises – the Delhi high court in its interim order on Monday attached all assets of RHC Holdings and Oscar Investments.
New Delhi: The Supreme Court on Thursday refused to pass any interim order to permit banks to sell shares pledged by Malvinder Singh and Shivinder Singh in Fortis Healthcare Holding Pvt. Ltd.
New Delhi: Religare Enterprises Ltd, promoted by brothers Shivinder Singh and Malvinder Singh, told on Wednesday the Delhi high court that the sale of its health insurance business is unlikely to happen this year.
New Delhi: The Supreme Court on Friday directed former Ranbaxy promoters, Malvinder and Shivender Singh, to maintain status quo with regard to their stake in Fortis Healthcare Ltd.
The Delhi High Court on Tuesday asked RHC Holdings and Oscar Investments (companies owned by former Ranbaxy promoters Malvinder and Shivinder Singh) to respond by August 10 to a contempt application filed against them by Japanese pharmaceutical major Daiichi Sankyo.
The order to allow conditional stake sale by Singh brothers in Fortis Healthcare was passed to afford protection to Daiichi Sankyo in terms of ready realizable value of assets at a later stage
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...